PURPOSE: Sarcoidosis impacts quality of life in many different ways; as a multisystem disease sarcoidosis may place not only physical demands on patients (pts) but emotional burdens as well.The therapy of such a disease impacts the health related quality of life too.
METHODS: 81 biopsy positive sarcoidosis pts were analyzed. The average duration of the disease was 5, 5 years, ranging from 1-8yrs. 17 male (21%) and 64 female (79%). The average age 47,28yrs. All pts completed the CES-D scale as a simple self report depression measure. The CES-D scale has 20 items; a final score of 16 and higher indicates depression.
RESULTS: CES-D score higher than 16 meaning depression have 63 (77, 8%) pts: 17,5% male and 82,5% female pts. The mean CES-D score for all patients was 23,15 SD 8,18.Female patients were more likely to be depressed than male. The CES-D score regarding the clinical form of the disease (acute/chronic) does not differ significantly between the groups.( Kruskal-Wallis variance analyses). Patients with extra pulmonary sarcoidosis have higher CES-D score (24, 14) than those with pulmonary disease only (22, 36), but the difference was not statistically significant. Pulmonary sarcoidosis have 77,8% of pts in this analyzed group. The CES-D score differs significantly between the pts with the I stage of the lung sarcoidosis (mean CES-D score 21,6) and the pts with the III stage of the lung disease (mean CES-D score 35). ANOVA 0,015. Analyses of CES-D scores regarding different therapy regimes showed no statistical difference between the groups: patients with no therapy , pts on steroid therapy and patients treated with methotrexate. ANOVA between the groups 0, 32.
CONCLUSION: The number of sarcoidosis patients with the CES-D score >16 indicating depression is quite high. (78%). Sarcoidosis impacts patient's personality in many different ways. Depression is only one, but knowing the fact, we will have to deal with it properly.
CLINICAL IMPLICATIONS: Possible predictors of depression in sarcoidosis require special attention of the clinicians.
DISCLOSURE: Violeta Vucinic, No Financial Disclosure Information; No Product/Research Disclosure Information